AU721489B2 - Treatment of type II diabetes mellitus with amylin agonists - Google Patents

Treatment of type II diabetes mellitus with amylin agonists Download PDF

Info

Publication number
AU721489B2
AU721489B2 AU62685/96A AU6268596A AU721489B2 AU 721489 B2 AU721489 B2 AU 721489B2 AU 62685/96 A AU62685/96 A AU 62685/96A AU 6268596 A AU6268596 A AU 6268596A AU 721489 B2 AU721489 B2 AU 721489B2
Authority
AU
Australia
Prior art keywords
amylin
insulin
pro
patients
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU62685/96A
Other languages
English (en)
Other versions
AU6268596A (en
Inventor
Orville G Kolterman
John F. Mullane
Robert G. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of AU6268596A publication Critical patent/AU6268596A/en
Application granted granted Critical
Publication of AU721489B2 publication Critical patent/AU721489B2/en
Assigned to ASTRAZENECA PHARMACEUTICALS LP, AMYLIN PHARMACEUTICALS, INC. reassignment ASTRAZENECA PHARMACEUTICALS LP Alteration of Name(s) in Register under S187 Assignors: AMYLIN PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU62685/96A 1995-06-07 1996-06-07 Treatment of type II diabetes mellitus with amylin agonists Ceased AU721489B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/483,188 US6143718A (en) 1995-06-07 1995-06-07 Treatment of Type II diabetes mellutis with amylin agonists
US08/483188 1995-06-07
PCT/US1996/009875 WO1996040220A1 (en) 1995-06-07 1996-06-07 Treatment of type ii diabetes mellitus with amylin agonists

Publications (2)

Publication Number Publication Date
AU6268596A AU6268596A (en) 1996-12-30
AU721489B2 true AU721489B2 (en) 2000-07-06

Family

ID=23919034

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62685/96A Ceased AU721489B2 (en) 1995-06-07 1996-06-07 Treatment of type II diabetes mellitus with amylin agonists

Country Status (19)

Country Link
US (2) US6143718A (enExample)
EP (1) EP0772451B1 (enExample)
JP (1) JP4009319B2 (enExample)
AT (1) ATE228849T1 (enExample)
AU (1) AU721489B2 (enExample)
BG (1) BG101230A (enExample)
CA (1) CA2196999C (enExample)
CZ (1) CZ289043B6 (enExample)
DE (1) DE69625157T2 (enExample)
DK (1) DK0772451T3 (enExample)
ES (1) ES2187659T3 (enExample)
HU (1) HUP9700368A3 (enExample)
IN (1) IN181672B (enExample)
NO (1) NO970519L (enExample)
PT (1) PT772451E (enExample)
RU (1) RU2166958C2 (enExample)
SK (1) SK18697A3 (enExample)
WO (1) WO1996040220A1 (enExample)
ZA (1) ZA964838B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1995007098A1 (en) * 1993-09-07 1995-03-16 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
ES2316161T3 (es) * 1998-01-09 2009-04-01 Amylin Pharmaceuticals, Inc. Formulaciones para peptidos agonistas de amilina con insulina.
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
EP1474164B1 (en) * 2002-01-08 2008-10-29 Amylin Pharmaceuticals, Inc. Use of amylin, amylin analogs and amylin derivatives to treat dyslipidemia and triglyceridemia
JP4579681B2 (ja) * 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
MXPA05012278A (es) * 2003-05-14 2006-02-10 Emisphere Tech Inc Composiciones para suministrar peptido yy y combatientes pyy.
WO2005014022A1 (en) * 2003-07-16 2005-02-17 Develogen Aktiengesellschaft Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
RU2385878C2 (ru) 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
WO2006099288A2 (en) * 2005-03-11 2006-09-21 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
AU2007210862A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkB agonist
CA2672750A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
EP2219664A1 (en) * 2007-11-14 2010-08-25 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8071537B2 (en) * 2008-06-25 2011-12-06 Endo Pharmaceuticals Solutions Inc. Implantable device for the sustained release of a polypeptide
EP2317975B1 (en) 2008-06-25 2016-04-13 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
EP2405934B1 (en) * 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
CN106687474A (zh) * 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010146A1 (en) * 1991-11-19 1993-05-27 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
WO1995007098A1 (en) * 1993-09-07 1995-03-16 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
WO1993010146A1 (en) * 1991-11-19 1993-05-27 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor

Also Published As

Publication number Publication date
IN181672B (enExample) 1998-08-29
NO970519D0 (no) 1997-02-05
HUP9700368A2 (hu) 1998-06-29
HUP9700368A3 (en) 2001-03-28
ZA964838B (en) 1997-02-24
DK0772451T3 (da) 2003-01-06
CZ33797A3 (en) 1997-07-16
AU6268596A (en) 1996-12-30
US6143718A (en) 2000-11-07
CA2196999C (en) 2012-09-04
EP0772451B1 (en) 2002-12-04
CA2196999A1 (en) 1996-12-19
WO1996040220A1 (en) 1996-12-19
EP0772451A1 (en) 1997-05-14
CZ289043B6 (cs) 2001-10-17
DE69625157D1 (de) 2003-01-16
SK18697A3 (en) 1998-02-04
NO970519L (no) 1997-04-07
JP4009319B2 (ja) 2007-11-14
PT772451E (pt) 2003-04-30
ATE228849T1 (de) 2002-12-15
BG101230A (en) 1997-10-31
DE69625157T2 (de) 2003-04-17
JPH10503785A (ja) 1998-04-07
ES2187659T3 (es) 2003-06-16
RU2166958C2 (ru) 2001-05-20
US6417164B1 (en) 2002-07-09
EP0772451A4 (en) 1998-09-30
HU9700368D0 (en) 1997-04-28

Similar Documents

Publication Publication Date Title
EP0772451B1 (en) Treatment of type ii diabetes mellitus with amylin agonists
CA2171207C (en) Methods for regulating gastrointestinal motility
US7910548B2 (en) Methods for treating obesity
US6136784A (en) Amylin agonist pharmaceutical compositions containing insulin
EP0981360B1 (en) Method for preventing gastritis using amylin or amylin agonists
US20120196799A1 (en) Amylin Family Peptides and Methods for Making and Using Them
CN1163572A (zh) 用淀粉样肽激动剂治疗ii型糖尿病

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)